In 2025, the company reported a modest +1.29% YoY revenue growth, shaped largely by its core portfolio: Keytruda ($31.68B) continues to dominate as one of the worlds top-selling oncology drugs with expanding indications, Gardasil/Gardasil 9 ($5.23B) remains a key growth driver in vaccines despite some demand fluctuations, and Januvia/Janumet ($2.54B) continues to decline as generic competition intensifies
It is very tricky, because theyll put that big GLP-1 on there and it makes you think, Well, maybe this is the drug, if youre not thinking about how to read these labels or if you dont know how to read these labels, Alan said
While it reversed the declining trend in 2021, it still lags significantly behind Keytruda, with sales nearly half of the latter's
Because they're classed as food supplements, they don't go through the same safety checks as prescription medications
Patients who already have reflux, constipation, irritable bowel symptoms, gallbladder history, diabetes medications, kidney concerns, low blood pressure, limited appetite, or difficulty maintaining protein intake should be especially proactive
Does morning or evening dosing affect GLP-1 side effects
